No Data
No Data
H.C. Wainwright Maintains Biomea Fusion(BMEA.US) With Buy Rating, Maintains Target Price $40
Biomea Fusion Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Positive Buy Recommendation for Biomea Fusion Amid Promising Diabetes Treatment Developments in COVALENT-111 Phase 2 Trial
Express News | D. Boral Capital Maintains Buy on Biomea Fusion, Maintains $128 Price Target
Biomea Fusion Announces Late-Breaker Oral Presentation Showing New Analysis From The Escalation Portion Of COVALENT-111 Presented At The 1st Annual Asian Conference On Innovative Therapies For Diabetes Management; Icovamenib Achieves A Mean Reduction...
Biomea Fusion's Icovamenib Shows Efficacy in Type 2 Diabetes Trial
No Data
No Data
Trytosaveabit : Because it’s forward looking towards their Pipeline especially their Diabetes treatment! GL
soyabean89 OP Trytosaveabit : the reaction since the last earning is too radical even when there are update on the diabetic drugs... I can't phantom and dumbfounded entire week lol
Shootingstar : hope go to 32 soon
soyabean89 OP Shootingstar : their diabetic drug research is the make or break factor lol... the previous tanking to 4dollar was due to they stop a drug study and wanted to focus on the diabetic drug. prelim result look promising... have pray for fda approval
Shootingstar soyabean89 OP : I kena burn by a opiod pharma company before so I scared scared of pharma stocks since then. they make these opoids but stronger then morphine think maybe the evil fentanyl or something instead haha. read something those fda likely to become CEO of pharma companies. this industry quite orh am one. I pray yours is genuine and is a success. this one $APPLIED BIOSCIENCES CORP (APPB.US)$ . they dilute and wipe me out. I dulan and write email to ask how can they dilute me to zero. they said for any information contact 3rd party responsible for their trading activities. I just see look like they mati. hope Kennedy junior will punish them
View more comments...